ISOLATION AND CHARACTERIZATION OF AMNION-DERIVED INHIBITORY FACTORS ON LYMPHOCYTE PROLIFERATION by D. Rossi
Università degli Studi di Milano
Scuola di Dottorato in Medicina Molecolare
Curriculum di Genomica, Proteomica e Tecnologie correlate
Ciclo XXIV
Anno Accademico 2011/2012
TESI DI DOTTORATO DI RICERCA
BIO10/E05
ISOLATION AND CHARACTERIZATION OF 
AMNION-DERIVED INHIBITORY FACTORS ON 
LYMPHOCYTE PROLIFERATION
Dottorando: Daniele ROSSI
Matricola n°: R08115
Tutore: Prof.ssa Cristina BATTAGLIA
Correlatore: Dr. Ornella PAROLINI
Direttore della Scuola: Ch.mo Prof. Mario Clerici

ABSTRACT
Background
Cells derived from the amniotic membranes of human term placenta are 
receiving particular attention because of their characteristics of stemness, 
multipotency and their immunologycal features, supporting a variety of 
possible clinical applications in the field of cell  transplantation and 
regenerative medicine. We have previously demonstrated that cells isolated 
from the mesenchymal region of the human amniotic membrane (human 
amniotic mesenchymal tissue cells, hAMTC) possess immunoregulatory 
properties, such as the ability to inhibit lymphocyte proliferation and 
cytokine production and to suppress generation and maturation of 
monocyte-derived dendritic cells, as also reported for MSC from other 
sources. All of the results described above were obtained when hAMTC 
were cultured either in direct cell contact or in a transwell  system, thereby 
suggesting the involvement of soluble inhibitory factor(s) secreted by these 
cells. However, the precise factors and mechanisms responsible for the 
immunoregulatory roles of hAMTC remain unknown.
Aims
Therefore, in this study, we aimed to identify the soluble factors released by 
hAMTC which are responsible for the anti-proliferative effects of these cells 
on lymphocytes, and also to gain insight into the mechanisms underlying 
their actions through in vitro studies. 
Materials and Methods
Conditioned medium (CM) was prepared by culture of isolated hAMTC 
(CM-hAMTC) and fragments of the whole human amniotic membrane (CM-
hAM) for 5 days in UltraCulture medium. Chemical and physical properties, 
such as the thermostability, chemical nature and molecular weight, of the 
factors associated with the anti-proliferative effects of hAMTC were 
evaluated. Blocking of specific synthetic pathways involved in the 
production of immunomodulatory factors, such as nitric oxide, kynurenine 
and prostaglandins, was achieved by adding specific inhibitors during CM 
production. Finally, the involvement of certain cytokines in the 
antiproliferative effects of the CM was evaluated by adding neutralizing 
antibodies to the CM during lymphocyte proliferation tests.
Results 
In this study, we have demonstrated that: 
• the inhibitory factors are temperature-stable, have a small molecular 
I
weight, and are likely to be non-proteinaceous; 
• only inhibition of the cyclooxygenase pathway partially reversed the anti-
proliferative effects of hAMTC, suggesting that prostaglandins may be 
key effector molecules in this phenomenon;
• factors which have been previously documented to play a role in the 
inhibitory effects of MSCs from other sources (HGF, TGF-β, NO and 
IDO) were not shown to be involved; 
• the anti-proliferative effects of the amniotic membrane are intrinsic to 
this tissue and its derived cells, since these effects are manifested in the 
absence of stimulating culture conditions, as opposed to MSC derived 
from the bone marrow, which possess anti-proliferative ability only when 
cultured in the presence of activating stimuli.
Conclusions
We have demonstrated that both isolated cells or the amniotic membrane in 
toto are capable of releasing factors that present with immunomodulatory 
capacity, thereby providing new insights toward the identification of some of 
these factors and toward the characterization of other factors which remain 
to be identified.
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SOMMARIO
Introduzione
Le cellule derivate dalle membrane amniotiche della placenta umana a 
termine stanno ricevendo particolare attenzione per le loro caratteristiche di 
staminalità, multipotenza e per le loro proprietà immunologiche, 
suggerendo una varietà di possibili applicazioni cliniche nel campo del 
trapianto di cellule e della medicina rigenerativa. Nel nostro laboratorio 
abbiamo precedentemente dimostrato che le cellule isolate dalla regione 
mesenchimale della membrana amniotica umana (hAMTC per amniotic 
mesenchymal tissue cells) possiedono, così come riportato anche per MSC 
isolate da altre fonti, la capacità di inibire la proliferazione dei linfociti e la 
produzione di citochine da parte degli stessi e di sopprimere la generazione 
e la maturazione di cellule dendritiche derivate da monociti. Questi  risultati 
sono stati ottenuti sia quando le hAMTC sono state utilizzate in un sistema 
di co-cultura diretta, sia in un sistema di transwell, suggerendo il 
coinvolgimento di fattori solubili secreti da queste cellule. Tuttavia, i fattori 
coinvolti e i meccanismi responsabili di questa azione immunoregolatoria 
da parte delle hAMTC rimangono tuttora non chiari.
Scopo
In questo studio, attraverso analisi in vitro, abbiamo cercato di identificare i 
fattori solubili rilasciati  da hAMTC e responsabili degli effetti antiproliferativi 
di queste cellule, oltre che i possibili meccanismi alla base della loro 
azione. 
Materiale e metodi
Il terreno condizionato (CM) è stato recuperato dopo 5 giorni di coltura, in 
terreno UltraCulture, di hAMTC (CM-hAMTC) e frammenti di membrana 
amniotica umana (CM-hAM). Abbiamo valutato le proprietà chimico-fisiche, 
analizzando la termostabilità, la natura chimica e il peso molecolare, dei 
fattori responsabili  degli effetti  antiproliferativi. Inoltre, abbiamo valutato il 
ruolo di molecole note per essere coinvolte nelle azioni immunomodulatorie 
delle MSC isolate da altre fonti, come l’ossido nitrico, la chinurenina e le 
prostaglandine, bloccando specificamente le loro vie biosintetiche durante 
la produzione dei CM. Infine abbiamo valutato il coinvolgimento di 
selezionate citochine nell’effetto antiproliferativo dei CM, utilizzando 
anticorpi neutralizzanti specifici durante il test di prliferazione linfocitaria.
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Risultati
Abbiamo quindi dimostrato che:
• i fattori inibitori sono stabili a cambiamenti di temperatura, hanno un 
basso peso molecolare e sono probabilmente di natura non proteica;
• l’inibizione dell’enzima cicloossigenasi induce una parziale riduzione 
dell’effetto antiproliferativo delle hAMTC, suggerendo che le 
prostaglandine possano essere importanti molecole effettrici  di questo 
fenomeno;
• fattori precedentemente documentati aventi un ruolo negli effetti inibitori 
di MSC isolate da altre fonti (come HGF, TGF-β, NO e IDO) non sono 
coinvolti nell’azione delle hAMTC;
• gli  effetti antiproliferativi della membrana amniotica e delle cellule 
derivate da essa sono intrinseche in questo tessuto, poiché questi effetti 
si  manifestano in assenza di condizioni di coltura stimolanti, al contrario 
di MSC derivate dal midollo osseo che possiedono la capacità anti-
proliferativa solo quando coltivate in presenza di stimoli attivatori.
Conclusioni
Abbiamo dimostrato che sia le cellule isolate che la membrana in toto sono 
in grado di rilasciare fattori solubili con capacità immunomodulatoria. Inoltre 
abbiamo fornito una parziale, seppur importante, identificazione di alcuni di 
questi fattori e qualche indicazione sulle caratteristiche delle sostanze 
ancora sconosciute.
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1. INTRODUCTION
1.1 The placenta 
1.1.1 Structure of human term placenta 
The placenta is the organ that plays an essential role in development of the 
growing embryo by facilitating gas and nutrient exchange between the 
mother and fetus. The placental sac is expelled in the final phase of labour, 
following its detachment from the uterine wall which is provoked by the 
quick reduction in uterine volume after the emerging of the neonate. 
The human term placenta is round or oval in shape with a diameter of 
15-20 cm and a thickness of 2-3 cm. Within the placental tissue, it is 
possible to distinguish the trophoblast and the fetal membranes (Fig. 1.1). 
The fetal membranes (amnion and chorion) extend from the margins of  the 
trophoblast and enclose the fetus in the amniotic cavity. The umbilical cord 
insert into the fetal face of the placenta, and from this the fetal blood 
vessels originate (Fig. 1.1).
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Figure 1.1. Human term placenta. (A) Internal surface (in contact with the fetus). 
The trophoblast becomes thinner toward the edge, continuing to the fetal 
membranes (amnion and chorion). The umbilical  cord inserts into the fetal side of 
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the trophoblast, and contains fetal blood vessels. (B) External  surface (in contact 
with the maternal  uterine wall). The trophoblast becomes subdivided into irregular 
lobed structures, termed cotyledons. (C) Lateral view of placenta.
The placenta is a fetomaternal organ, with the maternal portion being 
composed of the decidua which is derived from the maternal endometrium; 
while the fetal portion is composed of  the placental disc and the amniotic 
and chorionic membranes. 
The placental disc (Fig. 1.2) is composed of the chorionic plate and the 
basal plate, which form a cover and bottom, respectively, to surround the 
intervillous space. The chorionic plate is a multilayered structure that faces 
the amniotic cavity, and consists of  two different structures, namely, the 
amniotic membrane and the chorion. From the chorionic plate originate the 
villi that anchor the placenta through the trophoblast of the basal plate to 
the endometrium. From the maternal side, protrusions of the basal plate 
within the chorionic villi produce the placental septa, which divide the 
parenchyma into irregular cotyledons (Fig. 1.2). 
Figure 1.2. Schematic section of human term placenta. 
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plate Amnionchorionic membrane Umbilical cord 
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Some villi anchor the placenta to the basal plate, whereas other terminate 
freely in the intervillous space where maternal blood flows. Inside the villi 
there are fetal vessels that are connected to the circulatory system via the 
chorionic plate and the umbilical cord. Fetal blood is carried to the villi via 
the branches of  the umbilical arteries. After circulating through the 
capillaries of the villi, the fetal blood absorbs oxygen and nutritional 
materials from, and transfers waste products to the maternal blood through 
the villous walls. The purified and nourished fetal blood is then carried back 
to the fetus via the umbilical vein. 
At the placental margin, the intervillous space is obliterated so that the 
chorionic plate and the basal plate fuse with each other forming the 
chorionic membrane, which together with the amniotic membrane, encloses 
the fetus in the amniotic cavity. 
The amniotic membrane (Fig. 1.3) or amnion is a thin, avascular 
membrane composed of an uninterrupted single layer of cuboidal and 
columnar epithelial cells (termed the amniotic epithelium) which is bathed in 
amniotic fluid and is contiguous over the umbilical cord with the fetal skin. 
The amniotic epithelium is attached to a distinct basement membrane that 
is, in turn, connected to the amniotic mesoderm, an acellular compact layer 
composed of collagens I, III and fibronectin. Deeper in the amniotic 
mesoderm, a network of dispersed fibroblast-like mesenchymal cells and 
rare macrophages are observed.  Next to the amniotic membrane lies the 
chorionic membrane (Fig. 1.3), consisting of  the chorionic mesoderm and 
the chorionic trophoblast. A spongy layer of loosely arranged collagen fibers 
separates the amniotic and chorionic mesoderm, both of  which are similar 
in composition. The chorionic trophoblast, which lies on the top of the 
mesodermal layer, is a highly variable layer of extravillous trophoblast cells. 
Toward the endometrium, the trophoblast interdigitates extensively with the 
decidua [1,2].
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Figure 1.3. Cross-sectional representation of human fetal membranes 
(amnion and chorion). The amnion is composed of a monolayer of epithelial  cells, 
which rest on a mesodermal layer. The chorionic membrane consists of a 
mesodermal layer and a layer of extravillous trophoblast cells. Abbreviations: AE, 
amniotic epithelium; AM, amniotic mesoderm; CM, chorionic mesoderm; CT, 
chorionic trophoblast. (Giemsa staining) 
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Figure 3. Cross-sectional representation of human fetal membranes (amnion and 
chorion). The amnion is composed of a monolayer of epithelial cells, which rest on a 
mesoder al layer. The chorionic membrane consists of a mesodermal layer and a layer 
of extravillous trophoblast cells. Abbreviations: AE, amniotic epithelium; AM, amniotic 
mesoderm; CM, chorionic mesoderm; CT, chorionic trophoblast. (Giemsa staining) 
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1.1.2 Embryological development of the placenta 
Development of the placenta begins as soon as the blastocyst implants in 
the maternal endometrium (6-7 days after fertilization). At this stage, the 
blastocyst is a flattened vesicle in which most of the cells form an outer wall 
(trophoblast) which surrounds the blastocystic cavity (blastocoel). A small 
group of  larger cells, known as the inner cell mass, is apposed to the inner 
surface of the trophoblastic vesicle (Fig. 1.4). 
Figure 1.4. Representation of the blastocyst at six days after fertilization. 
(Adapted from [3]). 
The trophoblast gives rise to the chorion, whereas the fetus, the umbilical 
cord and the amnion are derived from the inner cell mass. 
As the blastocyst adheres to the endometrial epithelium, the invading 
trophoblast erodes the deciduas, allowing the embedding of the blastocyst. 
During implantation, the trophoblastic cells of  the implanting pole of  the 
blastocyst show  increased proliferation, resulting in a bi-layered trophoblast 
made up of  a multinucleated outer syncytiotrophoblast which originates 
from fusion of neighboring trophoblast cells, and an inner, mononucleated 
cytotrophoblast layer (Fig. 1.5). 
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The proliferating cytotrophoblast and the syncytiotrophoblast give rise to a system 
of trabeculae intermingled with hematic  lacunae. From these trabeculae are 
generated the primordial villi. 
Figure 1.5. Attachment of the blastocyst to the endometrial epithelium. 
(Adapted from [3]). 
At day 8-9 after fertilization, morphological changes occur in the inner cell 
mass, which differentiates into two layers termed the epiblast and the 
hypoblast, that together form the bilaminar embryonic disc (Fig. 1.6). From 
the epiblast, some small cells appear between the trophoblast and the 
embryonic disc and enclose a space that will become the amniotic cavity 
while the cells themselves will eventually constitute the amniotic epithelium. 
The three germ layers of  the embryo (endoderm, mesoderm, ectoderm) will 
also originate from the epiblast. 
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On the opposite side, between the hypoblast and the cytotrophoblast, the 
exocoelomic membrane and the remainder of  the blastocystic cavity modify 
to form the yolk sac. The extraembryonic mesoderm arranges into a 
connective tissue that surrounds the yolk sac and the amniotic cavity, giving 
rise to the mesoderm of both the amnion and the chorion. 
Figure 1.6. Formation of the bilaminar embryonic disc. (Adapted from [3]). 
Both the amnion and chorion originate in the first two weeks after 
fertilization, before the commencement of gastrulation during the third 
week, whereby the bilaminar disc differentiates into the three germ layers 
(ectoderm, mesoderm and endoderm) [2,3] (Fig. 1.7). 
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Figure 1.7. Schematic representation of the development of embryonic and 
extraembryonic tissues within the first 20 days after formation of the zygote 
(Adapted from [3]).
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1.2 Amniotic membrane-derived cells 
As previously described, the amniotic membrane is a thin, avascular 
membrane composed of an epithelial layer and an outer layer of  connective 
tissue, and is contiguous, over the umbilical cord, with the fetal skin. The 
amniotic epithelium (AE) is an uninterrupted, single layer of flat, cuboidal 
and columnar epithelial cells in contact with amniotic fluid. It is attached to a 
distinct basal lamina that is, in turn, connected to the amniotic mesoderm 
(AM) (Fig. 1.8). In the amniotic mesoderm closest to the epithelium, an 
acellular compact layer is distinguishable, composed of collagens I and III 
and fibronectin. Deeper in the AM, a network of  dispersed fibroblast-like 
mesenchymal cells and rare macrophages are observed. Very recently, it 
has been reported that the mesenchymal layer of amnion indeed contains 
two subfractions, one having a mesenchymal phenotype and the second 
containing monocyte-like cells [4].
Figure 1.8. Human amniotic membrane composition.
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The nomenclature utilized for amniotic membrane-derived cells, i.e. hAEC 
and hAMSC to indicate human amniotic epithelial cells and human amniotic 
mesenchymal stromal cells, respectively, was adopted following the “First 
International Workshop on Placenta Derived Stem Cells” in 2007 [5]. From 
the data presented by the participants of  that meeting, the following points, 
amongst others, were highlighted:
✓ cells isolated from placental tissue should be verified to be of fetal origin; 
✓ four regions of fetal placenta can be distinguished, i.e. amniotic epithelial, 
amniotic mesenchymal, chorionic mesenchymal, and chorionic 
trophoblastic. From these regions, the following cell populations are 
isolated: human amniotic epithelial cells (hAEC), human amniotic 
mesenchymal stromal cells (hAMSC), human chorionic mesenchymal 
stromal cells (hCMSC), and human chorionic trophoblastic cells (hCTC).
1.2.1 Human amniotic epithelial cells (hAEC)
Human amniotic epithelial cells (hAEC) are cuboidal to columnar cells that 
arise from the embryonic epiblast and are amongst the first cells to 
differentiate from the conceptus [5,6]. 
Recent reports indicate that hAEC express stem cell markers and have the 
ability to differentiate toward all three germ layers [7]. These properties, the 
ease of isolation of the amniotic cells and the plentiful availability of 
placenta as a discard tissue, make the amnion a potentially useful and 
noncontroversial source of  cells for transplantation and regenerative 
medicine. For isolation of epithelial cells, the amniotic membrane is stripped 
from the underlying chorion and digested with trypsin [8-11]. A detailed 
protocol is available providing a step-by-step isolation procedure along with 
photos of the process [12]. Isolated cells readily attach to plastic or 
basement membrane-coated culture dishes. Culture is commonly 
established in a simple medium such as Dulbecco’s modified Eagle’s 
medium supplemented with 5-10% serum and epidermal growth factor 
(EGF), where the cells proliferate robustly and display typical cuboidal 
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epithelial morphology [10,11,13] (Fig. 1.9). Normally, 2–6 passages are 
possible before proliferation ceases. Cells do not proliferate well at low 
densities. 
A B 
Figure 1.9. Phase micrographs showing cuboid morphology of cultured hAEC at 
passage 0 (A) and at passage 3 (B).
The amniotic membrane contains epithelial cells which express different 
surface markers, suggesting some heterogeneity of phenotype. 
Immediately after isolation, hAEC appear to express very low  levels of 
human leukocyte antigen (HLA)-A,B,C [11]; however, by passage 2, 
significant levels are observed [10,14-16]. Additional cell surface antigens 
on hAEC include ATP-binding cassette transporter G2 (ABCG2/BCRP), 
CD9, CD24, E-cadherin, integrins α6 and β1, c-met (hepatocyte growth 
factor receptor), stage-specific embryonic antigens (SSEAs) 3 and 4, and 
tumor rejection antigens (TRA) 1-60 and 1-81 [10,17]. Surface markers 
thought to be absent on hAEC include SSEA-1, CD34, and CD133, 
whereas other markers, such as CD117 (c-kit) and CCR4, are either 
negative or may be expressed on some cells at very low  levels. Although 
initial cell isolates express very low  levels of CD90 (Thy-1), the expression 
of this antigen increases rapidly in culture [10,17]. 
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In addition to surface markers, hAEC express molecular markers of 
pluripotent stem cells, including octamer-binding protein 4 (OCT-4), SRY-
related HMG-box gene 2 (SOX-2), and Nanog [10]. 
The suggestion that hAEC may be pluripotent was supported by the report 
by Tamagawa et al. [18]. These investigators created a xenogeneic chimera 
of human amnion cells with mouse embryonic stem cells, in vitro, obtaining 
chimeric aggregates which showed human contribution to all three germ 
layers. Later studies indicated that differentiation of hAEC can be directed, 
with Sakuragawa et al. identifying neural and glial markers on cultured 
hAEC [19]. Later studies reported that cultured hAEC synthesize and 
release acetylcholine, catecholamines [9,20,21], and dopamine [22,23]. 
Hepatic differentiation of  hAEC has also been reported. In particular, 
Sakuragawa et al. reported that cultured hAEC produce albumin (Alb) and α-
fetoprotein (AFP) and that Alb- and AFP-positive hepatocyte-like cells could 
be identified integrated into hepatic parenchyma following transplantation of 
hAEC into the livers of severe combined immunodeficiency (SCID) mice [24]. 
The hepatic potential of  hAEC was later confirmed and extended 
[10,25,26], whereby in addition to Alb and AFP production, other hepatic 
functions, such as glycogen storage and expression of liver-enriched 
transcription factors, such as hepatocyte nuclear factor (HNF) 3γ and 
HNF4α, CCAAT/enhancer-binding protein (CEBP α and β), and several of 
the drug metabolizing genes (cytochrome P450) could be demonstrated. 
The wide range of  hepatic genes and functions identified in hAEC suggests 
that these cells may be useful for liver-directed cell therapy.
Differentiation of hAEC to another endodermal tissue, pancreas, has also 
been reported. Wei et al. [27] reported that after culture of hAEC for 2–4 
weeks in the presence of nicotinamide to induce pancreatic differentiation, 
transplantation of  the insulin-expressing hAEC corrected the hyperglycemia 
in streptozotocin-induced diabetic mice. 
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1.2.2 Human amniotic mesenchymal stomal cells (hAMSC)
The mesodermal region of the amniotic membrane contains mesenchymal 
cells that are dispersed in an extra-cellular matrix which is composed 
largely of collagen and laminin. The mesenchymal cells themselves are 
derived from the extraembryonic mesoderm [6], and originate during the 
pre-gastrulation stages of embryogenesis before the delineation of  the 
three primary germ layers [5,6].
In accordance with the guidelines set out during the “First International 
Workshop on Placenta Derived Stem Cells” in 2007 [5], as well as the 
criteria proposed by Dominici et al. for bone marrow-derived mesenchymal 
stromal cells [28], mesenchymal cells isolated from amniotic membranes 
are termed amniotic mesenchymal stromal cells (hAMSC). 
Indeed, the minimal criteria for defining hAMSC are as follows: 
✓ adherence to plastic;
✓ formation of fibroblast colony-forming units;
✓ a specific pattern of surface antigen expression (Table 1.1);
✓ differentiation potential toward one or more lineages 
 (including osteogenic, adipogenic, chondrogenic, and vascular/
 endothelial); 
✓ fetal origin. 
Positive (>95%) Negative (<2%)
CD90 CD45
CD73 CD34
CD105 CD14
HLA-DR
Table 1.1. Specific surface antigen expression at passages 2-4 for amniotic 
mesenchymal stromal cells (Adapted from [5]).
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hAMSC can be isolated from first-, second-, and third-trimester mesoderm 
of amnion [14,15,29-32]. Here, when using the terms hAMSC we refer to 
cells from term placenta unless otherwise specified. 
Isolation of hAMSC is usually performed with term amnion dissected from 
the deflected part of the fetal membranes to minimize the presence of 
maternal cells. hAMSC populations can be obtained by different 
procedures, which are based essentially on digestion of the amniotic 
membrane with collagenase [33] or collagenase and DNase [34]. hAMSC 
show  a fibroblastoid shape, and are able to adhere to and proliferate on 
tissue culture plastic and can be kept until passages 5–10 (Fig. 1.10). 
A B 
Figure 1.10. Phase micrographs showing fibroblastoid morphology of cultured 
hAMSC at passage 0 (A) and at passage 3 (B).
Expression of  CD49d (α4 integrin) on hAMSC distinguishes them from 
hAEC [15], while, in culture, neither vimentin nor cytokeratin 18 expression 
is specific for hAMSC or hAEC, respectively. Transmission electron 
microscopy of hAMSC shows mesenchymal and epithelial characteristics, 
and this hybrid phenotype is interpreted as a sign of multipotentiality. 
Transmission electron microscopy of  hAMSC show  a simpler cytoplasmic 
organization of these cells, the most notable features of which include the 
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presence of stacks of rough endoplasmic reticulum cisternae, dispersed 
mitochondria and glycogen lakes. Meanwhile, features of higher 
specialization, such as presence of  assembled contractile filaments, 
prominence of endocytotic traffic, and junctional communications, are 
lacking [35]. The surface marker profile of  cultured hAMSC and 
mesenchymal stromal cells (MSC) from adult bone marrow  are similar, in 
that all express typical mesenchymal markers (Table 1.1) but are negative 
for hematopoietic (CD34 and CD45) and monocytic markers (CD14) 
[14,15,30,32]. While surface expression of  SSEA-3 and SSEA-4 and RNA for 
OCT-4 has been reported [15,27,36-38] in hAMSC,  immunofluorescence 
staining of  mesenchymal tissue itself  has failed to detect SSEA-3 or SSEA-4 
[39]. 
hAMSC differentiate toward “classic” mesodermal lineages (osteogenic, 
chondrogenic, and adipogenic) [14,15,30,32,36], and differentiation of 
hAMSC to all three germ layers - ectoderm (neural) [14,31], mesoderm 
(skeletal muscle [16,36], cardiomyocytic [37,40] and endothelial [36]) and 
endoderm (pancreatic) [27] - has been reported. However, questions 
remain as to the proportion of  hAMSC that exhibit plasticity and whether the 
progeny are indeed able to undergo full maturation [39].
Human amniotic cells have been reported to successfully and persistently 
engraft in multiple organs and tissues in vivo. Indeed, human chimerism 
has been detected in the brain, lung, bone marrow, thymus, spleen, kidney, 
and liver after either intraperitoneal or intravenous transplantation of  human 
amnion and chorion cells into neonatal swine and rats, indicating active 
migration of these cells, which was consistent with their observed 
expression of adhesion and migration molecules (L-selectin, VLA-5, CD29, 
and P-selectin ligand 1), as well as cellular matrix proteinases (MMP-2 and 
MMP-9) [41].
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1.2.3 Human amniotic mesenchymal tissue cells (hAMTC)
As described above cells derived from the mesenchymal region of the 
amnion showed the characteristics of hAMSC when cultured; however, a 
defined population of HLA-DR-expressing cells with macrophage-monocyte 
phenotypic characteristics has also been described in the mesenchymal 
layer of  the amnion [42-44], thus suggesting the presence of  populations 
capable of active immune function within these tissues.
Indeed, Magatti et al. [4] have confirmed the presence of  two distinct 
subpopulations in the mesenchymal region of  amnion which differ in their 
expression of CD45, CD14, and HLA-DR. Considering that mesenchymal 
stromal cells from different origins are agreed to be negative for these 
markers [5,28], the unfractionated population derived from the 
mesenchymal region of amnion, which includes both HLA-DR-positive and 
-negative cells, has therefore been designed as human amniotic 
mesenchymal tissue cells (hAMTC). Furthermore, since freshly isolated 
cells at passage 0 are described in this study, we will adopt the 
nomenclature hAMTC.
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1.3 Immunology and placenta 
1.3.1 Fetomaternal tolerance
Immunologically, pregnancy is an exceptional phenomenon whereby the 
fully competent immune system of the mother is rendered tolerant to the 
immunologically distinct fetal allograft, thereby creating a situation in which 
rejection, which would normally ensue in an allogeneic transplantation 
setting in the absence of immunosuppression, is avoided. The paradox of 
maternal immunological tolerance to the fetus was first raised more than 50 
years ago by Peter Medawar, who proposed three hypotheses to explain 
the phenomenon: i) that there is a physical separation between the mother 
and the fetus, ii) that the fetus is antigenically immature, and iii) that the 
mother possesses an immunological inertness [45]. Since the time of 
Medawar, it has become evident that these mechanisms cannot fully 
explain why the fetus is not rejected by the mother, and other site-specific 
immune suppression mechanisms must therefore be considered. Indeed, 
several studies have indicated that the fetal placental barrier may be less 
inert or impervious than previously envisioned, with evidence presented for 
cellular trafficking in both directions across the fetal/maternal interface 
[46-48]. With regard to the second mechanism of  Medawar’s paradox, it 
has been shown that fetal cells do in fact express MHC I and MHC II which 
are antigenically mature and detectable in maternal circulation [49]. Finally, 
it is also now  clear that the maternal immune system is not inert during 
pregnancy, and it can in fact respond to and eliminate fetal cells that enter 
the maternal circulation [47,50]. 
Many local mechanisms that contribute to protection of  the fetus from the 
maternal immune system have been identified at the fetomaternal interface, 
although it is not yet clear how these mechanisms interact with each other. 
For example, It has been shown that trophoblastic cells express the non 
classical HLA molecules HLA-E, and HLA-G [51]. In particular, HLA-G has 
been shown to inhibit natural killer cells that could induce fetal rejection 
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[49]. Meanwhile, it has been hypothesised that the effect of HLA-G on NK 
cell activity is not induced directly, but rather, that it also requires the 
expression of HLA-E on trophoblastic cells [52,53]. In addition, soluble 
HLA-G molecules produced by placenta induce apoptosis of  activated 
CD8+ T cells and inhibit CD4+ T-cell proliferation [54]. Moreover, the 
interaction of HLA-G with dendritic cells through KIR-related leukocyte Ig-
like receptors may have an indirect effect on the immune response by 
tolerizing dendritic cells and facilitating the generation of regulatory T cells 
[55,56]. 
Other explanations have also been proposed regarding the regulation of 
maternal T-cell proliferation at the maternal interface. One such suggestion 
is that Indoleamine 2,3-dioxygenase (IDO) plays a role in promoting 
fetomaternal tolerance [57]. This tryptophan catabolising enzyme is 
produced by some cells of the syncytiotrophoblast, and it is thought to 
prevent immune responses to the fetus by inhibiting maternal T cell 
activation either by depriving T cells of  tryptophan [58] or by producing 
catabolites of tryptophan (kynurenine) which prevent activation and 
proliferation of T cells, B cells and NK cells [59]. However, in IDO knockout 
mice, fetus rejection was not observed [60] and so, although IDO activity 
has been suggested as a key mechanism for protecting the allogenic fetus, 
it is not the sole determinant in this process, and other mechanisms can 
compensate for the loss of IDO activity during gestation. 
Other studies have shown that trophoblast cells express Fas ligand, which 
is able to induce apoptosis of activated maternal Fas-expressing 
lymphocytes [61]. Therefore, this Fas/FasL system could also contribute to 
the maintenance of fetomaternal tolerance. 
1.3.2 Immunologic properties of fetal membranes
Whether the fetus participates actively in suppressing maternal allogeneic 
immune responses and, if so, which fetal placental tissues exert these 
immunomodulatory effects, are both questions which remain to be 
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addressed. Evidence which provides support to the hypothesis that fetal 
membranes are non-immunogenic comes from clinical studies in which 
amniotic membrane has been used for treatment of  skin wounds, burn 
injuries, chronic leg ulcers, and prevention of tissue adhesion in surgical 
procedures [62-68]. Amniotic membrane is also used in ocular surface 
reconstruction to promote the development of normal corneal or conjuntival 
epithelium [69,70] without acute rejection in absence of  immunosuppressive 
treatment. Moreover, several clinical trials in humans have proven that 
allogeneic transplantation of amniotic membrane [71-73] or hAEC [8,74] does 
not induce acute immune rejection in the absence of immunosuppressive 
treatment.
Intriguingly, in vitro experiments using supernatants from short term 
cultures of human placenta have demonstrated inhibition of PHA- 
(phytoheamaglutinin-) driven lymphocyte activation, mixed lymphocyte 
reaction and natural killer activity [75], while additional experiments have 
shown that fragments of amniotic membrane exert immunosuppressive 
properties in mixed lymphocyte reactions [76]. 
Furthermore, both human amniotic membrane and human amniotic 
epithelial cells have been shown to survive for prolonged periods of time 
after xenogeneic transplantation into immuno-competent animals, including 
rabbits [77], rats [51], guinea pigs [78] and bonnet monkeys [79]. 
Additionally, long-term engraftment has been observed after intravenous 
injection of  human amniotic and chorionic cells into newborn swine and 
rats, with human microchimerism detected in several organs [41], 
suggesting active migration and tolerogenic potential of the xenogeneic 
cells. Finally, long-term survival of  rat amnion-derived cells, with no 
evidence of immunological rejection or tumor formation, has been observed 
after allogeneic in utero transplantation of these cells into the developing 
rodent brain [80].
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1.3.3 The paracrine immunomodulatory action of amnion 
membrane and its derivatives 
Several lines of evidence support the possibility that placental tissue or 
cells may be capable of  exerting immunomodulatory actions. For example, 
considering the fundamental role played by the placenta in the 
phenomenon of fetomaternal tolerance, it is conceivable that cells isolated 
from placental tissues might have immunomodulatory properties. 
Meanwhile, given that mesenchymal cells present in the bone marrow 
stroma have been shown to exert immunomodulatory effects, it is plausible 
that this property could also be displayed by mesenchymal cells that are 
isolated from placental tissues. 
Indeed adult mesenchymal stromal/stem cells (MSC), which were first 
identified in bone marrow  (BM) [81], but have since been successfully 
isolated from various other sources, including umbilical cord blood [82], 
adipose tissue [83], peripheral blood [84], amniotic fluid [85], Wharton’s 
Jelly [86,87], and more recently from different tissue of  human placenta [5], 
have been extensively studied both for their ability to differentiate towards 
multiple lineages, such as cells of  the bone, cartilage, muscle, adipose, 
tendons and central nervous system [88-90], as well as for their interesting 
immunoregulatory properties [91-93]. Numerous in vitro studies have 
demonstrated that MSC can target and modulate the function of different 
cells of the immune system, such as T cells [94], B cells [95], natural killer 
cells [96] and dendritic cells [97,98]. 
These in vitro immunomodulatory properties have generated enormous 
interest in the potential application of  MSC in vivo as an immunosuppressive 
cellular therapy. Successful results have been obtained with the use of  MSC 
for both the prevention of graft-versus-host disease (GVHD) in solid organ 
transplantation [99,100] and for the treatment of steroid-resistant acute 
GVHD, which arises after allogeneic hematopoietic cell transplantation 
[101,102]. Moreover, systemic infusion of MSC has been shown to 
ameliorate the clinical and histopathological severity of experimental 
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autoimmune encephalomyelitis [103], multiple sclerosis [104], and colitis 
[105]. 
In recent years, our laboratory (Centro di Ricerca E. Menni, Fondazione 
Poliambulanza-Istituto Ospedaliero, Brescia) has demonstrated that cells 
with characteristics of MSC can be successfully isolated from the human 
amniotic and chorionic membranes [32,41]. 
In particular, we have shown that a mix of cells isolated from the 
mesenchymal region of  both human amnion and chorion fail to induce 
allogeneic T-cell responses and actively suppress T-cell proliferation 
induced by alloantigens [41]. Moreover, after intravenous injection of 
heterogeneous human amniotic and chorionic cells into newborn swine or 
rats, human microchimerism was detected in bone marrow, brain, lung, and 
thymus, suggesting active migration and integration into specific organs, 
and therefore indicating active tolerance [41].
Interestingly, Magatti et al. have shown, through in vitro studies, that human 
amniotic mesenchymal tissue cells (hAMTC) not only fail to induce 
allogeneic lymphocyte activation in vitro, but also actively suppress 
lymphocyte proliferation in an allogeneic mixed lymphocyte reaction (MLR) 
or induced by T-cell receptor engagement. This effect was observed when 
the hAMTC were present both in direct cell contact or when cultured in a 
transwell system (which impedes cell contact) [4].
In addition, this same group has demonstrated that the presence of hAMTC 
strongly inhibited differentiation of monocytes into iDC, preventing the 
expression of  the DC marker CD1a and reducing the expression of HLA-
DR, CD80, and CD83 [97]. Moreover, exposure to LPS of monocytes 
cultured with GM-CSF and IL-4 and in the presence of  hAMTC resulted in 
lack of CD83 and CD80 upregulation, reduced CD86 and HLA-DR 
expression, and a final cell phenotype very similar to the original 
monocytes. It was also observed that the presence of hAMTC in 
differentiating DC cultures results in the arrest of  the cells to the G0 phase 
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and abolishes the production of  inflammatory cytokines such as TNF-α, 
CXCL10, CXCL9 and CCL5. 
Through co-culture experiments, Magatti and co-workers also revealed that 
hAMTC significantly reduced the proliferative activity of  different tumor cell 
lines, and that this effect was cell-dose-dependent [106]. This anti-
proliferative effect was observed both when hAMTC and tumor cells were 
co-cultured in contact or physically separated in a transwell system. 
Notably, the anti-proliferative effect of hAMTC were shown not to be 
exerted through induction of tumor cell apoptosis, but rather, through cell 
cycle arrest in the G0/G1 phase [106].
All of the results described above were obtained when hAMTC were 
cultured either in direct cell contact or in a transwell system, thereby 
suggesting the involvement of soluble inhibitory factor(s) secreted by these 
cells, although the identities of such factors remain to be elucidated.
In support of a key role of  soluble factors in the suppressive action of 
amniotic membrane-derived cells, Cargnoni and colleagues reported use of 
a mouse model of lung fibrosis to show  that a reduction of severity and 
progression of  the disease can be obtained not only after the 
transplantation of amniotic membrane-derived cells, but also after the 
injection of their conditioned medium generated from culture of  these cells 
[107,108]. Indeed, the extent, severity and progression of lung fibrosis in 
mice after bleomycin instillation were reduced in mice which had also been 
treated with conditioned medium from hAMTC culture (CM-hAMTC) when 
compared to animals of the control group [108].
Likewise, Cargnoni and colleagues demonstrated that application of an 
amniotic membrane fragment (hAM) onto ischemic rat hearts could 
significantly reduce postischemic cardiac dysfunction [109], with amniotic 
membrane-treated rats showing higher preservation of cardiac dimensions 
and improved cardiac contractile function in terms of  higher left ventricle 
ejection fraction, fractional shortening, and wall thickening. However, no 
engraftment of amniotic cells was detected into host cardiac tissues, all 
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together suggesting that the amniotic membrane may constitute a 
convenient vehicle for supplying cells that produce cardioprotective soluble 
factors, and also reinforcing the notion that this tissue constitutes a cell 
source with clinical potential that has yet to be completely revealed.
Moreover, Sant’anna and co-workers have demonstrated that hAM 
patching onto livers of  rats subjected to bile duct legation (BDL) reduced 
the severity and progression of BDL-induced fibrosis [110]. Indeed, while 
fibrosis progressed rapidly in untreated control rats, leading to cirrhosis 
within 6 weeks, fibrosis in hAM-treated rats was confined at the portal/
periportal area with no signs of  cirrhosis, while collagen deposition was 
reduced to about 50% of levels observed in control rats. In addition, the 
hAM was able to significantly slow  the gradual progression of the ductular 
reaction and reduce the area occupied by activated myofibroblasts at all 
time points analyzed in the study [110]. Interestingly, like Cargnoni and 
colleagues, these authors also failed to detect donor cells in host liver.
In summary, it is clear that the beneficial effects observed after the 
application of the amniotic membrane onto the ischemic rat heart [109] and 
the fibrotic rat liver [110] are very likely induced by paracrine actions 
exerted on host tissues by bioactive molecules secreted by the amniotic 
cells, further suggesting the involvement of soluble factors as the key 
actors in the anti-inflammatory and anti-fibrotic effects of the amniotic cells.
1. Introduction
23
2. AIM OF THE STUDY
Both in vitro and in vivo studies have provided evidence to support the 
immunoregulatory role of  MSC [94-105]. However, the exact mechanisms 
underlying this immunomodulatory function still remain to be fully 
elucidated. Factors such as indoleamine 2,3-dioxygenase (IDO) enzyme, 
nitric oxide (NO), prostaglandin E2 (PGE2), tumor growth factor (TGF)-β, 
interleukin (IL)-10, hepatocyte growth factor (HGF) and galectins have all 
been reported to be associated with the immunosuppressive effects of 
human MSC isolated from bone marrow  [92]. Nevertheless, conflicting 
results have been reported to date regarding the specific contribution of 
these factors in MSC-mediated immuno-regulatory processes [92,93]. In 
addition, even though is widely accepted that the mechanism of action of 
MSC derived from the amniotic membrane is also associated with the 
release of soluble factors, no studies so far have reported the 
characterization of these factors.
Therefore, the main aim of this study was to identify the various 
immunomodulatory soluble factors released by hAMTC and to shed light on 
the mechanisms underlying the effects of  these factors on lymphocyte 
proliferation.
To this end, we firstly prepared conditioned medium (CM) from the culture 
of hAMTC and fragments of the whole human amniotic membrane (hAM), 
and then tested whether the immunomodulatory properties of these 
conditioned media were affected by either addition of  specific antibodies 
against certain cytokines, blockage of  specific biochemical pathways, or 
different chemical treatments. 
We first analyzed the thermostability, chemical nature, and molecular 
weight of the factors associated with the anti-proliferative effects of hAMTC. 
We then assessed the effects of blocking the activity of specific molecules, 
and also investigated the role of  factors known to be involved in the 
immunomodulatory actions of MSC from other sources.
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Finally, through the blockage of distinct biochemical pathways, such as 
those responsible for IDO metabolism, or nitric oxide production or 
prostaglandin production, we gained insight into the identity of the factors 
involved in the immunomodulatory proprties of amniotic membrane-derived 
cells.
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3. MATERIAL AND METHODS 
3.1 Ethics statement
Human term placentas, bone marrow  (BM) aspirates and peripheral blood 
were obtained from donors after informed consent according to the 
guidelines of Ethical Committee of  the Catholic Hospital (CEIOC). For all 
samples used throughout our study, informed written consent was sought 
and obtained from each single donor. The research project was authorized 
by Centro di Ricerca E. Menni-Fondazione Poliambulanza Commitee, 
which specifically approved this study.
3.2 Human sample collection, cell isolation and culture
3.2.1 Isolation and culture of human amniotic mesenchymal 
tissue cells (hAMTC)
Human term placentas were processed immediately after birth using a 
previously described protocol [32], with some modifications. The amnion 
was manually separated from the chorion and washed extensively in 
phosphate-buffered saline (PBS; Sigma, St Louis, MO, USA) containing 
100 U/ml penicillin and 100 µg/ml streptomycin (herein referred to as P/S), 
(both from Euroclone, Whetherby, UK) and 2.5 µg/ml amphotericin B 
(Lonza, Basel, CH). Afterwards, the amnion was cut into small pieces (3 × 3 
cm2). Amnion fragments were sterilized by a brief incubation in PBS + 2.5% 
Eso Jod (Esoform, Italy) and 3 min in PBS containing 500 U/ml penicillin, 
500 µg/ml streptomycin, 12.5 µg/ml amphotericin B and 1.87 mg/ml 
Cefamezin (Pfizer, Italy). Sterilized amnion fragments were then incubated 
for 9 min at 37°C in HBSS (Lonza, Basel, CH) containing 2.5 U/ml dispase 
(Roche, Mannheim, Germany). After a 3 min resting period at room 
temperature in RPMI 1640 medium (Cambrex, Verviers, Belgium) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma), 
2 mM L-glutamine (Cambrex) and P/S, the fragments were digested with 
0.94 mg/ml collagenase (Roche) and 20 µg/ml DNase (Roche) for 2.5-3 hrs 
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at 37°C. Amnion fragments were then removed, mobilized cells were 
passed through a 100 µm cell strainer (BD Falcon, Bedford, MA), and 
collected by centrifugation at 280 x g for 10 min. These cells, as reported 
above, are referred to as hAMTC, for human amniotic mesenchymal tissue 
cells. 
To obtain hAMTC at different passages, freshly isolated cells were plated at 
a density of  50 x 103/cm2. Upon reaching confluency, adherent cells were 
trypsinized and then sub-cultured at a density of 20 x 103/cm2 untill 
passages 3.
3.2.2 BM-derived MSC isolation and culture
Bone marrow  (BM) aspirates were extracted from the femoral heads of 
patients undergoing orthopedic surgery and processed as follows. Briefly, 
BM samples were diluted (1:4) in PBS + P/S, transferred to 50 ml conical 
tubes (Falcon) and centrifuged at 1500 x g for 15 min. After discarding of 
the fat layer and supernatant, the cells were layered on a density gradient 
(Lymphoprep, Axis Shield) and centrifuged at 670 × g for 30 min. 
Recovered mononuclear cells were then collected, washed twice with PBS 
and centrifuged at 280 × g for 10 min before being plated at a density of  8 x 
105/cm2 in DMEM (Lonza), supplemented with 10% heat-inactivated FBS, 
L-glutamine and P/S and maintained in culture at 37°C with 5% CO2. After 
3 days, non-adherent cells were removed. Upon reaching confluency, 
adherent cells (BM-MSC) were trypsinized and sub-cultured at a density of 
8 x 103/cm2, and were used for experiments at passage 3.
3.2.3 Human peripheral blood mononuclear cells (PBMC)
PBMC were obtained from heparinized whole blood samples or buffy coats 
from healthy subjects using density gradient centrifugation (Lymphoprep, 
Axis-Shield).
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3.3 Flow cytometry analysis
For evaluation of cell phenotype, cell suspensions were incubated for 20 
minutes at 4°C with fluorescein isothiocyanate or phycoerythrin-conjugated 
antibodies specific for human CD90 (clone 5E10), CD73 (clone AD2), CD13 
(clone L138), CD44 (clone L178), CD105 (clone SN6), CD166 (clone 3A6), 
CD45 (clone H130), HLA-DR (clone TU36), and CD34 (clone AC136), or 
isotype controls IgG1 (clone X40), IgG2a (clone X39), and IgG2b (clone 
MG2b-57). All monoclonal antibodies were obtained from BD Biosciences 
(San Jose, CA,) except for isotype control IgG2b, which was obtained from 
Biolegend. Samples were analyzed with a FACSCalibur instrument and the 
CellQuest software (BD Biosciences).
3.4 Polyuretan foam scaffold production 
Prof. Tanzi and colleagues (Biomaterials Laboratory, Politecnico of Milan) 
provided PUF matrix (EF) that was synthesized by reacting a polyether-
polyol mixture with MDI prepolymer, using Fe-acetyl-acetonate as a 
catalyst, and water as an expanding agent, essentially as previously 
described [112,113], with the exception that the polyether-polyol mixture 
used in this case had higher hydrophilicity than that previously described. 
Density, porosity and average pore size, by micro CT (Skyscan 1172, 
Aartselaar, Belgium), were then evaluated (Fig.3.1). 
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Figure 3.1. Micro CT scan of EF PUF foam. (A) 3D model of the EF PUF foam 
generated through the micro CT algorithm adaptive rendering; (B) trend of the 
foam average pore size distribution.
For experimental approach used in this study, 2 different type of scaffolds 
were employed, namely, uncovered EF PU foam or EF PU foam covered 
with Tri-Calcium-Phosphate (α-TCP), made by fixing EF discs (Ø=6 mm) in 
circular slots in a polymeric mesh, followed by coating through immersion in 
α-TCP suspension under magnetic stirring.
3.5 In vitro hAMTC osteogenic differentiation
hAMTC, isolated from human placenta as previously described, were 
suspended in culture medium at a density of  5 x 106/ml. Cell suspension 
(100 µl/well) were seeded into glass two-well chamber slides or onto each 
EF PUF specimen, placed in an incubator (5% CO2, 37°C) and maintained 
under static culture conditions for the entirety of the study (3 weeks).
Osteogenic differentiation was assessed by incubating plated cells (in glass 
chambers slides or on EF PUF scaffolds) in NH OsteoDiff  Medium (Miltenyi 
Biotec) or in Eagle’s Minimum Essential Medium (EMEM), as control, for 3 
weeks at 37°C with 5%CO2. Media was changed every 3 days. 
A B 
3. Material and methods
29
3.6 Osteogenic differentiation evaluation
3.6.1 Histological and cytological stainings
After 3 weeks EF PUF foam samples which had been cultured with 
hAMTC, were fixed in formalin for 24h, dehydratated in a graded series of 
ethanol and embedded in paraffin. Sections of  3µm thickness were then 
stained with hematoxylin-eosin for scaffold colonization and cell distribution 
analysis, or with Alizarin Red (Sigma) or von Kossa (Bio-Optica) for calcium 
deposit evaluation.
At the same time point, the cells which had been differentiated in glass 
chamber slides were fixed with Bio-Fix (Bio-Optica) and air-dry for the 
cytological analysis. Osteoblasts were identified by cytochemical staining 
for alkaline phosphatase (ALP), using a commercial kit (86-R; Sigma) as 
previously described [114]. Calcium deposits, characteristic of  osteogenic 
differentiation in cultures, were visualized by alizarin red (Sigma) and von 
Kossa staining (Bio-Optica) according to the manufacturer’s instructions.
3.6.2 RNA extraction and RT-PCR analysis
Both on the day of  isolation, and also at the end of osteogenic 
differentiation culture in glass chamber slides, hAMTC were resuspended in 
RLT buffer (Qiagen) for the molecular analysis. Total RNA was isolated from 
the undifferentiated and the osteogenic differentiated hAMTCs using the 
EZ1 RNA Cell Mini Kit (Qiagen) according to the manufacturer’s 
instructions, and the yield was determined spectrophotometrically at 
260/280 nm. Equal amount of  RNA (100 ng) from each sample were 
reverse transcribed into cDNA (Improm II Reverse Transcription System, 
Promega) and PCR was performed using a GoTaq polymerase kit 
(Promega). Oligonucleotide primers and an amplification profile specific to 
each gene marker analyzed in this study are presented in Table 3.1. RT-
PCR products were run on a 1.5% agarose gel and visualized by staining 
with ethidium bromide. 
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!Target gene Primers sequence
Product size 
(bp)
Annealing
temperature 
(°C)
Number of
cycles
5'-GAAGGTGAAGGTCGGAGT-3'
5'-GAAGATGGTGATGGGATTTC-3'
5'-ACGTCGCTAAGAATGTCATC-3'
5'-CTGGTAGGCGATGTCCTTA-3'
5'-TGACGAGACCAAGAATCTG-3'
5'-CCATCCAAACCACTGAAACC-3'
5'-TCTGCAACATGCAGACTGGC-3'
5'-GAAGCAGACAGGCCCTATGT-3'
5'-AACATGACCTATCCAAGCGC-3'
5'-ACGATTCTCCATCATCCTCC-3'
5'-ATGGGTGAAACTCTGGGAG-3'
5'-CCTTGCATCCTTCACAAGC-3'
5'-GCCCAAGATGGTGACTCG-3'
5'-ATGGCGTCGTCCACCTTC-3'
Abbreviation: GAPDH=Glyceraldehyde 3-phosphate dehydrogenase; Sox9=SRY-box 9; PPAR-2!=Peroxisome proliferator-activated receptor !2
275 58 25GAPDH
Alkaline phosphatase
Collagen I
55 35
Collagen II
Sox9
PPAR-2!
Mushashi-I
475
599
517
114 58 35
55 35143
40481 56
58 40
55 35
Table 3.1. Primers sequences and amplification profile.
3.7 Production of conditioned medium (CM)
The different conditioned media (CMs) used in this study were obtained as 
follows.
3.7.1 CM generated from freshly isolated hAMTC
hAMTC (obtained from amniotic membranes of  at least 80 different donors) 
at passage 0 were re-suspended in an opportune volume of complete 
UltraCulture medium, composed of  UltraCulture medium (Lonza) 
supplemented with P/S, and plated in 24-well plates (Corning Inc., Corning, 
NY) at different concentration: usually at 1 x 106 cells/well in a final volume of 
1 ml (referred to as CM-hAMTC) or, when otherwise specified, 0.5 x 105 cells/
well in 1ml (CM-hAMTC 0.5*106/ml), 0.25 x 105 cells/well in 1ml (CM-hAMTC 
0.25*106/ml) or 0.125 x 105 cells/well in 1ml (CM-hAMTC 0.125*106/ml).
3.7.2 CM generated from hAMTC at passage 3 (CM-hAMTC p3)
hAMTC at p3 (obtained from 3 different placentas) were plated in 24-well 
plates at a density of 2.5 x 105 cells/well in 0.5 ml of complete UltraCulture 
medium. 
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3.7.3 CM generated from the culture of fragments of the 
amniotic membrane (CM-hAM)
Sterilized fragments (3 cm x 3 cm) from freshly separated amniotic 
membranes (obtained from at least 50 different donors) were plated (1 
fragment in each well) in 6-wells plates (Corning Inc., Corning, NY) covered 
with a glass slide (Bio-Optica) and cultured in presence of  1 ml of  complete 
UltraCulture medium. One fragment of amniotic membrane contains a 
number of hAMTC comparable to that used for the production of  CM-
hAMTC (8 ± 4 x 105 hAMTC/ml).
3.7.4 CM generated from BM-MSC (CM-BM-MSC)
BM-MSC (obtained from 3 different BM donors) cultured untill passage 3, 
were plated in 24-well plates at a density of 2.5 x 105 cells/well in 0.5 ml of 
complete UltraCulture medium.
3.7.5 CM from cells that have been treated to block specific 
synthetic pathways
hAMTC (at passage 0) and hAM fragments (both obtained from at least 8 
different donors), were cultured in presence of the inhibitor of IDO activity 
(0.5 mM DL-methyl-tryptophan), the inhibitor of  NO synthase (1mM L-
NAME) or the inhibitors of cyclooxygenase (indomethacin, ketoprofen, 
niflumic acid), all purchased from Sigma-Aldrich. To determine the optimal 
dose of COX inhibitors able to decrease the quantity of  all prostanoids in 
both CM-hAMTC and CM-hAM, we previously performed experiments with 
different concentrations of the different COX inhibitors (i.e. 1, 5, 10, 50 and 
100 µM), (data not shown). We found that the highest reversion of  the 
inhibitory effect was obtained when using a concentration of  10 µM, which 
was the dose selected for further analysis.
All the cultures described above were performed at 37°C and 5% CO2 
atmosphere, for 5 days. At the end of this culture period, the different CMs 
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were collected, centrifuged at 300 x g, filtered through a 0.8 µm sterile filter 
(Sartorius), opportunely aliquoted under sterile conditions and frozen at 
-80°C until use.
Each CM preparation was tested for its ability of inhibiting lymphocyte 
proliferation, as explained below  in the paragraph describing lymphocyte 
proliferation test. For temperature stability analysis, proteinase K treatment 
and CM fractionation (described below), in order to obtain results that were 
less influenced by single donor variability and more representative of 
soluble factors released by hAMTC and hAM, we pooled 8 to 10 different 
CM-hAMTC or CM-hAM and used these pools for each specific analysis.
3.8 Temperature stability analysis 
CM-hAMTC and CM-hAM were subjected to different temperature changes. 
In particular, they were: i) incubated for 30 min at 60°C or 80°C; ii) 
subjected to three frost-defrost cycles, which were carried out by putting 
these CMs in liquid nitrogen and subsequently in a thermostatic bath at 
37°C. 
3.9 Proteinase K treatment
Complete UltraCulture medium, CM-hAMTC and CM-hAM (1 ml of  each 
sample) were treated with 1 U of proteinase K linked to agarose beads 
(Sigma-Aldrich), for 2 and 6 hours at 37°C. The digestion was then blocked 
by removing proteinase K through brief centrifugation. Proteinase-treated 
CMs were loaded on SDS-PAGE gels that were then stained by Coomassie 
blue. The efficacy of  protein digestion was evaluated monitoring the 
reduction of the density of  the band corresponding to BSA protein, which is 
the most abundant in CMs and complete UltraCulture medium. The band 
intensity was quantified using the Quantity One software (Bio-Rad).
3. Material and methods
33
3.10 CM fractionation
To obtain fractions potentially enriched in soluble factor(s) with inhibitory 
effects, different CM-hAMTC (n=11 pools) were fractionated using 
Centrifugal Filter Devices with different NMWL (Nominal Molecular Weight 
Limit) Ultracel membranes (Millipore). First, 3 ml of CM-hAMTC were 
loaded onto a Centrifugal Filter Device with Ultracel membranes with a 100 
kDa cut-off and centrifuged at 2700 x g for 35 min. Then, the solute was re-
suspended in the same volume of complete UltraCulture medium as the 
loaded sample, while the eluate was loaded onto a column with a 30 kDa 
membrane cut-off. After centrifugation at 2700 x g for 30 min, the solute 
was resuspended in complete UltraCulture (in the same volume as the 
loaded sample), while the eluate was reloaded onto a column with a 3 kDa 
membrane cut-off and centrifuged at 2700 x g for 35 min. Finally, the eluate 
was harvested and the solute was resuspended in complete UltraCulture 
medium. To analyze the potential interactions between factors, for several 
experiments we mixed different fractions. All the fractions were immediately 
tested for the ability to inhibit lymphocyte proliferation, as described below.
3.11 Lymphocyte proliferation test
Lymphocyte proliferation was induced either by stimulating PBMC (1 x 105/
well in 96-well-plate) by the addition of anti-CD3 (Orthoclone OKT3, 
Janssen-Cilag), (final concentration of 12.5 ng/ml) or by the co-culture with 
irradiated allogeneic “stimulator” PBMC [mixed leukocyte reaction (MLR)] at 
a 1:1 ratio. All cultures were carried out in triplicate in complete UltraCulture 
medium, and lymphocyte proliferation was assessed by adding [3H]-
thymidine for 16-18 hours after 3 (for PBMC + anti-CD3 stimulation) or 5 
(for MLR) days of culture. 
Proliferation inhibitors tested in these experiments were: (a) irradiated 
(3000 cGy) hAMTC or BM-MSC (1 x 105/well) put in contact or transwell 
with PBMC, in the absence or presence of 0.5 mM DL-methyl-tryptophan; 
(b) different amounts (50, 75, 100 µl/well) of CM-hAMTC, CM-hAM or CM-
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BM-MSC, with or without the addition of FBS (5%) and essential/non-
essential amino acids (Sigma); (c) different amounts of  CM-hAMTC and 
CM-hAM obtained after temperature- or proteinase K- treatment or after 
column fractionation; (d) different amounts of CMs generated after culture 
of hAMTC or hAM in presence of  specific inhibitors; (e) 100 µl of  different 
CMs after the addition of indomethacin (10 µM), DL-methyl-tryptophan (0.5 
mM), L-NAME (1 mM), a mixture of  PGs (mix 1: PGE2 500 ng/ml + PGD2 
100 ng/ml + PGF2α 25ng/ml or mix 2: PGE2 25 ng/ml + PGD2 6 ng/ml + 
PGF2α 10 ng/ml, all purchased from Cayman Chemical) or neutralizing 
antibodies against IL-10 (1 µg/ml, BD), IL-6 (1 µg/ml, BD), HGF (1 µg/ml, 
R&D Systems) and TGF-β (1 µg/ml, R&D Systems); (f) different amounts 
(from 10 pg/ml to 5 µg/ml) of PGE2, PGD2, PGI2, PGF2α or a mixture of 
these PGs (mix 1: PGE2 500 ng/ml + PGD2 100 ng/ml + PGF2α 25ng/ml; 
mix 2: PGE2 25 ng/ml + PGD2 6 ng/ml + PGF2α 10 ng/ml).
3.12 NO quantification
NO production in CM-hAMTC and CM-hAM was measured as nitrite (NO2-) 
accumulation, using the Griess reagent (G4410-Sigma Aldrich) and 
following manufacturer’s instructions. Serial NaNO2 dilutions in water were 
used to produce a standard curve. Absorbance was measured at 540 nm 
with a microplate reader (DV990/BV6-GDV).
3.13 Prostanoids quantification
Total prostanoids, prostaglandin (PG) E2, PGD2 and PGF2α quantification 
in CM-hAMTC and CM-hAM were obtained using the Cox Inhibitor 
Screening Assay Kit, Prostaglandin E2 EIA kit, Prostaglandin D2 EIA kit and 
Prostaglandin F2α EIA kit respectively (all purchased from Cayman 
Chemical) according to the manufacturer’s instructions. Absorbance was 
measured at 405 nm with a microplate reader. Since the manufacturer 
specifies that PGD2 monoclonal antibodies possess 92% cross reactivity 
with PGF2α, the amount of  PGD2 was calculated by subtracting 92% of the 
value obtained for PGF2α from the value obtained with the PGD2 antibody.
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3.14 Cytokine assay
The levels of  different cytokines in CM-hAMTC and CM-hAM were 
determined using a multiple cytometric beads array system (CBA Flex set, 
BD Biosciences), according to the manufacturer’s instructions. The 
following cytokines were measured: IL-2, IL-6, IL-8, tumor necrosis factor 
(TNF)-α, Fas-l, granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CFS), interferon-inducible 
protein (IP)-10, monocyte chemoattractant protein (MIP)-1α and β, 
oncostatin M (OSM) and RANTES (regulated upon activation, normal T-cell 
expressed and secreted). Samples were acquired with a FACSAria and 
analyzed with FCAP Array software (BD Biosciences).
The levels of  TGF-β and IL-10 were measured by sandwich enzyme-linked-
immunosorbent assay (ELISA) using a commercially available coupled 
antibody (respectively 555052-555053, and 554499-554497 from BD 
Biosciences) according to the manufacturer’s instructions. Concentrations 
were calculated from standards curves, and absorbance was measured at 
405 nm with a microplate reader. 
3.15 Kynurenine/tryptophan quantification
For these experiments the following were tested: CM-hAMTC, CM-hAM 
and CM derived from control MLR (CM-MLR) or from MLR performed in the 
presence of hAMTC (CM-MLR-hAMTC), with or without the addition of 0.5 
mM DL-methyl-tryptophan (CM-MLR-hAMTC+MT), which were harvested 
after 5 days of culture. 
One ml of phosphate buffer at pH 6.5 and 2 ml trichloroacetic-acid were 
added to 100 µl of  CM samples. The different CMs were incubated for 30 
min at 50°C and then centrifuged for 15 min at 4000 rpm. Two ml of  the 
supernatant were then used for solid phase extraction (SPE) using OASIS® 
HLB cartridges 1cc. Elution was ensued with 90% acetonitrile. The eluate 
was then dried by nitrogen and re-dissolved in 200 µl mobile phase for 
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HPLC analysis. IDO activity was measured as the ratio between kynurenine 
and tryptophan concentration determined by HPLC.
3.16 Statistical analysis
Data are expressed as mean ± SD. Student’s t-test were use to assess 
differences between groups. Raw  P-values were adjusted by Holm-
Bonferroni’s procedure for multiple comparison and differences were 
considered statistically significant for p values < 0.05.
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4. RESULTS
4.1 hAMTC phenotype and differentiation potential
4.1.1 hAMTC phenotypic characterization
Freshly isolated human amniotic mesenchymal tissue cells (hAMTC) were 
phenotypically characterised by FACS analysis. As shown in Table 4.1, at 
passage 0 hAMTC showed high positivity for CD90, CD73, CD13 and 
CD44, low  positivity for CD105, CD166, CD45, HLA-DR, CD14 and 
negativity for CD34.
Markers hATMC p0
CD90 82±3%
CD73 66±6%
CD13 89±2%
CD44 47±18%
CD105 6±4%
CD166 14±4%
CD45 6±3%
HLA-DR 6±3%
CD34 1±1%
Table 4.1. Phenotypical FACS analysis of freshly isolated hAMTC. Data are 
express as mean and standard deviation of positive cells percentage to considered 
markers.
4.1.2 hAMTC osteogenic differentiation
In order to evaluate the differentiation potential of hAMTC, we induced 
these cells to undergo osteogenic differentiation in vitro. 
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After 3 weeks of  culture on glass slides in the presence of  osteogenic 
medium, hAMTC showed calcium deposition, which was visualized by 
positive staining for alizarin red and von Kossa, as shown in Figure 4.1A. 
On the contrary, calcium  deposits were not present in cells cultured in control 
medium (Fig. 4.1A). Furthermore, in vitro osteoblastic differentiation, 
evaluated by the presence of  alkaline phosphatase (ALP) activity in 
cultured cells, was observed for hAMTC which had been cultured under 
osteogenic conditions, while hAMTC which had been cultured in control 
medium displayed no enzyme activity (Fig. 4.1A).
In order to evaluate gene expression during in vitro osteogenic 
differentiation, we analyzed the mRNA levels of  different markers which are 
specific to the three mesenchymal lineages (osteogenic, chondrogenic and 
adipogenic) in hAMTC cultured in osteogenic or control conditions. 
Interestingly, freshly isolated hAMTC present with basal level expression of 
ALP, Col-I, Col-II, Sox9, PPAR-2γ  and Musashi-1 (Fig. 4.1B). Through 
mRNA expression analysis, we observed that, after the 3 weeks of  culture, 
the expression of osteogenic-related genes (ALP and Col I) was 
upregulated in hAMTC which had been cultured in differentiation medium 
as compared to cells that had been cultured in control medium (Fig. 4.1B). 
On the contrary, we observed a down regulation in the expression of 
chondrogenic-related genes (Sox9 and Col-II) in the osteogenic 
differentiated cells (Fig. 4.1B). Moreover, we found that the mRNA of 
Musashi-1, a putative stem cell marker, is present in freshly isolated cells, 
and its expression was maintained after 3 weeks of culture in control 
medium, but  decreased dramatically after culture in osteogenic 
differentiation medium (Fig. 4.1B). Unexpectedly, the PPAR-2γ 
(Peroxisome Proliferator Activated Receptor-2γ) gene, which has been 
reported to be specific to the adipogenic lineage, presented with a high 
level of expression in hAMTC which had been cultured in osteogenic 
medium (Fig. 4.1B).
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Figure 4.1. In vitro osteogenic differentiation of hAMTC. (A) Representative 
cytological images of Alizarin red, von Kossa and Alkaline phosphatase staining of 
hAMTC cultured in presence of osteogenic or control medium for 3 weeks. (100x 
magnification). (B) Gene expression analysis on mRNA extracted from hAMTC on 
the day of cell isolation and after 3 weeks of culture in osteogenic or control 
medium. (ALP: alkaline phosphatase, Col I: collagen I, Col  II: collagen II; Marker: 
100bp DNA Ladder).
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In collaboration with Prof. Tanzi’s group, we have evaluated the osteogenic 
differentiation potential of  hAMTC which had been plated on 2 different 
polyuretan scaffolds, namely, EF PU foam or EF PU foam covered with Tri-
Calcium-Phosphate (α-TCP).
At 3 weeks post-seeding, a clear adhesion of hAMTC to the pore surface of 
PU foam was observed, in particular on EF PU foam which had been 
covered with α-TCP (Fig. 4.2A). Indeed, the pore surface was well 
colonized by the cells, which showed a well spread morphology (Fig. 4.2B).
Interestingly, alizarin red and von Kossa staining revealed calcium deposition 
in hAMTC plated on EF PU α-TCP even when the cells were cultured in the 
absence of osteoinductive medium. On the contrary, the cells which had 
been seeded on EF PU foam seems unable to produce a matrix containing 
high level of calcium, even when cultured under osteogenic induction 
conditions (Fig. 4.2A). As shown in Figure 4.2A, the best osteogenic 
differentiation was observed in cells which had been seeded on EF PU foam 
covered with α-TCP and cultured in osteogenic medium, suggesting the 
important role of the scaffold during osteogenic differentiation.
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Figure 4.2. In vitro osteogenic differentiation of hAMTC plated on PUF and α-
TCP-PUF. (A) Representative histological images of hematoxylin-eosin, alizarin red 
and von Kossa staining of hAMTC cultured on α-TCP-PUF or PUF in presence of 
osteogenic or control medium for 3 weeks. (100x magnification). (B) SEM images 
of PUF or α-TCP-PUF 3 weeks after hAMTC seeding in osteogenic or control 
medium. Cells are indicated by arrows while the extracellular matrix (ECM) is 
matked with *.
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4.2 Inhibitory effect of human amniotic membrane 
derivatives
4.2.1 Inhibitory effect of hAMTC, CM-hAMTC and CM-hAM on 
lymphocyte proliferation
It has previously been demonstrated that freshly isolated hAMTC inhibit 
lymphocyte proliferation in vitro [4]. Here we confirm that, under our 
experimental conditions, these cells inhibit lymphocyte proliferation, both 
when added in contact and in transwell settings (Fig. 4.3), thereby 
suggesting that the anti-proliferative effects of  hAMTC are associated with 
the production of yet unknown soluble factor(s). Herein we demonstrate 
that conditioned medium (CM) generated from the culture of freshly isolated 
non-stimulated hAMTC (CM-hAMTC) and from the culture of fragments of 
the amniotic membrane (CM-hAM), possess the ability to inhibit anti-CD3 
stimulated-T lymphocyte proliferation in a dose dependent manner (Fig. 
4.4A-B). We have also observed that when hAMTC are plated at lower 
concentration, the resulting CM present with lower inhibitory capacity when 
compared to CM derived from higher cell concentrations (Fig. 4.4A). 
Furthermore, the addition of essential and non-essential amino acids and 
FBS (5%) to the different CMs generated from hAMTC did not change the 
CMs’  inhibitory ability (Fig. 4.4C).
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Figure 4.3. Analysis of the antiproliferative effects of hAMTC. Effects of 
hAMTC on the proliferation of anti-CD3-stimulated lymphocytes (PBMC + αCD3) 
when added in a direct contact or transwell system. Data represent the mean and 
standard deviation (SD) of at least four independent experiments. ***=p<0.001.
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Figure 4.4. Analysis of the inhibitory effects of CM-hAMTC and CM-hAM. 
Effects of the following on the proliferation of anti-CD3-stimulated lymphocytes 
(PBMC + αCD3): (A) different amounts (50-100 µl) of CM derived from hAMTC 
plated at different concentration; (B) different amounts (50-75-100 µl) of CM-hAM; 
(C) 100 µl of control  medium or CM with (orange bars) or without (black bars) the 
addition of FBS (5%), essential and non-essential  aminoacids. Data represent the 
mean and standard deviation (SD) of at least six independent experiments. 
*=p<0.05, **=p<0.01, ***=p<0.001 versus PBMC + αCD3.
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Moreover we observed that both hAMTC at passage 3 and the CM derived 
from these cells (CM-hAMTC p3) maintain their anti-proliferative effects 
(Fig. 4.5). In contrast, even though BM-MSC were also able to inhibit T cell 
proliferation at  passage 3, CM derived from the culture of  these cells was 
not able to reduce T cell proliferation (Fig. 4.5), in accordance to previously 
reported findings [115,116]. 
Figure 4.5. Analysis of the inhibitory effect of hAMTC p3, BM-MSC p3 and of 
the respective CMs. Effects of the following on the proliferation of anti-CD3-
stimulated lymphocytes (PBMC + αCD3): hAMTC at passage 3 (red bar), BM-MSC 
at passage 3 (yellow bar) and different amounts (50-100 µl) of CM derived from the 
culture of these cells. Data represent the mean and standard deviation (SD) of at 
least four independent experiments. *=p<0.05, **=p<0.01, ***=p<0.001 versus 
PBMC + αCD3.
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4.2.2 Inhibitory soluble factor(s) characterization
4.2.2.1 Cytokine quantification and neutralization assay
We firstly quantified the levels of  a panel of inflammation-related molecules 
(see Table 4.2). Both CM-hAMTC and CM-hAM contain TNF-α, OSM, 
RANTES, GM-CFS, G-CFS, IL-6, IL-8, MIP-1α, MIP-1β, and TGF-β, but not 
Fas-ligand, IL-2 and IP-10. In contrast to CM-hAMTC, CM-hAM does not 
contain IL-10.
 Cytokine UltraCulture CM-hAMTC CM-hAMMedian MAD Median MAD Median MAD
 TNF-a 5 4 44 38 49 43
 Fas-l 0 0 8 8 6 6
 G-CFS 0 0 2271 287 2789 190
 GM-CFS 0 0 916 602 322 14
 IL-2 12 2 17 4 25 7
 IL-6 0 0 >10000 ND >10000 ND
 IL-8 0 0 2591 162 11527 673
 IP-10 0 0 10 9 0 0
 MIP-1α 0 0 12583 10006 7368 1095
 MIP-1β 3 1 3838 1519 5493 898
 OSM 0 0 190 174 70 37
 RANTES 0 0 265 152 53 3
 TGF-β* 0 0 464 204 209 209
 IL-10* 4 4 285 155 9 9
MAD: Median Absolute Deviation
Values are expressed in pg/ml * quantified by ELISA
Table 4.2. Cytokine quantification in UltraCulture medium, CM-hAMTC and CM-
hAM. 
To evaluate the involvement of several cytokines known to elicit anti-
proliferative effects when secreted by MSC from other sources (such as 
IL-10, IL-6, HGF, TGF-β) [92], we performed lymphocyte proliferation tests 
with CM-hAMTC and CM-hAM in the presence of neutralizing antibodies 
against IL-10, IL-6, HGF and TGF-β. 
The neutralization assay revealed that HGF and TGF-β are not involved in 
the CM inhibitory mechanism (Fig. 4.6B-C). Meanwhile, the addition of 
neutralizing antibodies against IL-10 and IL-6 showed a minimal reversion 
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effect without reaching a statistical difference (Fig. 4.6, panel  A and D). 
Similar minimal reversion was seen also when we used a cocktail of 
neutralizing antibodies against IL-10, IL-6, HGF and TGF-β (Fig. 4.6E). 
Figure 4.6. Inhibitory effect of CM-hAMTC and CM-hAM in presence of 
neutralizing antibodies. Lymphocyte proliferation, stimulated with anti-CD3 
(PBMC + αCD3), in presence of 100 µl  of control medium or CM with (orange bars) 
or without (black bars) the addition of neutralizing antibodies against IL-10 (A), 
TGF-β (B), HGF (C), IL-6 (D), mix of antibodies anti-IL-10, -TGF-β, -HGF and -IL-6 
(E). Data represent the mean and SD of at least four independent experiments. 
*=p<0.05, **=p<0.01 versus PBMC + αCD3.
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4.2.2.2 Temperature stability analysis and proteinase K treatment
To investigate whether the inhibitory potential of CM-hAMTC and CM-hAM 
is temperature-sensitive, we studied the anti-proliferative action of these 
CMs after exposuring them to temperature changes. After three frost-
defrost cycles, CM-hAMTC and CM-hAM showed the same inhibitory effect 
as the corresponding untreated CMs (Fig. 4.7A). CMs treated for 30 min at 
60°C or 80°C also still retained their anti-proliferative effect (Fig. 4.7B). The 
inhibitory potential was also preserved when these CMs were stored at 
-80°C for more than 1 year (data not shown). 
Figure 4.7. Effects of temperature changes on the anti-proliferative potential 
of CM-hAMTC and CM-hAM. Effects of the following on the proliferation of anti-
CD3-stimulated lymphocytes (PBMC + αCD3): (A) 100 µl of untreated CM-hAMTC 
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and CM-hAM (white bars) and of the corresponding CMs subjected to different 
frost-defrost cycles (coloured bars); (B) 100 µl of untreated (NT) control  medium 
(complete UltraCulture), CM-hAMTC, CM-hAM, and after incubation for 30 min at 
60°C or 80°C. Data represent the mean and SD of at least three independent 
experiments. *=p<0.05, ***=p<0.001 versus PBMC + αCD3.
Moreover, to determine whether the inhibitory component(s) in CM-hAMTC 
and CM-hAM has a proteinaceous feature, we developed a protocol to 
remove protein molecules from CMs based on proteinase K treatment. In 
our experimental condition six hours of  proteinase K treatment caused the 
digestion of  more than 90% of proteins present in the two CMs (Fig. 4.8A). 
Despite protein depletion, CM-hAMTC and CM-hAM maintained their anti-
proliferative activity (Fig. 4.8B). 
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Figure 4.8. Effect of proteinase K treatment on the inhibitory activity of CM-
hAMTC and CM-hAM. (A) Representative SDS-PAGE of untreated and proteinase 
K-treated (for 2 and 6 hrs) UltraCulture medium, CM-hAMTC and CM-hAM. 
Digestion level  was calculated as the reduction of the density of the BSA band 
(arrow). (B) Inhibitory effect on lymphocyte proliferation, induced by anti-CD3 
stimulation, of 100 µl of untreated (NT) and proteinase K-treated UltraCulture 
medium, CM-hAMTC and CM-hAM. Similar results were also obtained using 50 µl 
of CMs (data not shown). Data represent the mean and SD of at least five 
independent experiments. *=p<0.05, **=p<0.01 versus UltraCulture.
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4.2.2.3 Molecular weight of the inhibitory factor(s)
To establish the potential molecular weight of soluble inhibitory factor(s) 
present in the CM-hAMTC we subjected the CM to column fractionation. All 
the obtained fractions were then tested for their effects on lymphocyte 
proliferation. 
The fraction containing molecules with a molecular weight < 3 kDa (Fig. 
4.9A, grey bars) was the only fraction maintaining an inhibitory effect. 
Meanwhile, fractions obtained by unconditioned medium and used as 
controls did not show  any inhibitory effect (Fig. 4.9B). The results 
represented are obtained using 100 µl of  CM, however the same trend was 
observed using 50 or 75 µl of CM (data not shown).
The level of inhibition achieved with the fraction containing molecules < 3 
kDa was significantly reduced with respect to the level of the unfractionated 
CM (Fig. 4.9A, white bar).
In order to exclude the loss of components during fractionation protocol, all 
the fractions were re-pooled together and tested (Fig. 4.9A, CM-hAMTC 
fraction mix, white-grey-striped bar). CM-hAMTC fraction mix showed 
the same anti-proliferative effect of the unfractionated CM (Fig. 4.9A, white 
bar). 
Then, to find out whether soluble factor(s) present in different fractions may 
cooperate to exert an inhibitory ability, we mixed the single fractions two by 
two and tested the effects of  these new  preparations on T cell proliferation. 
All the mixes containing the fraction < 3 kDa had an inhibitory effect (Fig. 
4.9A, black-grey-striped bars), whilst only the mix containing the fraction 
of molecules > 100 kDa and < 3 kDa exerted an inhibitory effect statistically 
higher than that of  the fraction < 3 kDa alone. Furthermore, this mix had an 
inhibitory ability comparable to that of  the unfractionated CM. The 
preparation obtained by mixing the fraction 100-30 kDa and the fraction < 3 
kDa also had an inhibitory effect higher than the fraction < 3 kDa alone, but 
this difference did not reach a statistical significance.
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Figure 4.9. Study of the potential molecular weight of the inhibitory factor(s). 
(A) Lymphocyte proliferation, stimulated by anti-CD3, in presence of 100 µl  of CM-
hAMTC (white bar), CM-hAMTC-fraction-mix (grey bars) or mix of fractions with 
different molecular weights (white-grey- and black-grey-striped bars). (B) 
Lymphocyte proliferation, stimulated by anti-CD3, in presence of 100 µl of complete 
UltraCulture medium (black bar) or its fractions (grey and black-grey-striped bars). 
Data represent the mean and SD from at least six independent experiments. 
**=p<0.01, ***=p<0.001 versus PBMC + αCD3; #=p<0.05.
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4.2.2.4 Evaluation of Prostaglandins, Nitric Oxide and IDO involvement 
in CM-hAMTC and CM-hAM inhibitory effect
Based on the results obtained from the studies of  the molecular weight and 
the indication of the non-proteinaceous nature of the unknown inhibitory 
molecule(s), our next goal was to unravel the identity of these molecule(s). 
In order to do so, we evaluated the involvement of  known actors in 
immunomodulation that have low  molecular-weight and are not proteins, 
such as NO, kynurenine (a tryptophan metabolite) and PGs, in the anti-
proliferative ability of CM-hAMTC and CM-hAM. 
During CM production we therefore specifically inhibited: i) the NO 
synthesis, using L-NAME (L-Nitro-Arginine Methyl Ester), which is an 
inhibitor of  NO synthase; ii) the activity of IDO, which is one of  the key 
enzymes of  kynurenine biosynthesis [117], using DL-methyl-tryptophan and 
iii) the PGs production, using cyclooxygenase (COX) inhibitors (such as 
indomethacin, ketoprofen and niflumic acid). CMs obtained after inhibition 
of these factors were then tested for their effect on activated T-lymphocyte 
proliferation.
First, we observed that both CMs contain a low  amounts of NO, basically 
the same concentration as that found in the control medium (Fig. 4.10A). In 
addition, CM derived from hAMTC or hAM cultured in presence of  1mM L-
NAME had similar inhibitory effect of CMs derived from untreated samples 
(Fig. 4.10B). Taken together, these data indicate that NO is not responsible 
for the inhibitory effect of CM-hAMTC and CM-hAM, neither directly nor as 
mediator for the production of other inhibitory factors. 
The measurement of  IDO activity in CM-hAMTC (determined as the ratio 
kynurenine/tryptophan) revealed that hAMTC possess IDO activity when 
cultured alone, which increases when the cells are co-cultured with a MLR 
(as measured in the CM-hAMTC-MLR) (Fig. 4.10C). Despite the fact that 
the addition of DL-methyl-tryptophan during co-culture experiments 
dramatically decreases the IDO activity as measured in the CM (CM-MLR-
hAMTC+MT) (Fig. 4.10C), the inhibitory effect of hAMTC on lymphocyte 
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proliferation did not decrease in presence of  DL-methyl-tryptophan (Fig. 
4.10D). 
To further support the finding that the inhibitory effect of CM-hAMTC and 
CM-hAM seems independent of IDO activity, we added DL-methyl-
tryptophan during preparation of CMs (i.e. during hAMTC and hAM 
cultures). These CMs showed comparable inhibitory ability with respect to 
the CMs derived from untreated samples (Fig. 4.10E). 
Quantification of prostanoids in CM-hAMTC and CM-hAM revealed that 
amniotic cells produce a high amount of  COX products that could be 
partially responsible for the anti-proliferative effect of CM (Table 4.3). 
Indeed, CM-hAMTC and CM-hAM contain PGE2 (390±146 ng/ml and 24±2 
ng/ml, respectively), PGD2 (67±1 ng/ml and 6±1 ng/ml, respectively), and 
PGF2α (27±13 ng/ml and 10±1 ng/ml, respectively). The involvement of 
PGs in the CM’s inhibitory effect was confirmed by the addition of COX-
inhibitor during hAMTC or hAM culture. The indomethacin treatment 
decreased the concentration of all prostanoids in both CM-hAMTC and CM-
hAM, as shown in Table 4.3, and interestingly, the anti-proliferative ability of 
these CMs were partially reverted (Fig. 4.10F). Similar results were also 
obtained using other COX inhibitors, such as ketoprofen and niflumic acid 
(Fig. 4.10G-H). Even treatment with three COX inhibitors together 
(indomethacin, ketoprofen and niflumic acid) during CM-hAMTC and CM-
hAM production did not lead to a complete reversal of inhibitory effect (Fig. 
4.10I).
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Figure 4.10. NO, kynurenine, and prostaglandins (PGs) in CM-hAMTC and 
CM-hAM. (A) NO quantification (total nitrate quantification) in UltraCulture, CM-
hAMTC, and CM-hAM performed by means of the Griess test. (B) Lymphocyte 
proliferation (expressed in cpm) after stimulation with anti-CD3 and in presence of 
100 µl of complete UltraCulture medium, CM derived from untreated (black bar), or 
L-NAME-treated (white bar) hAMTC and hAM cultures. (C) IDO activity, shown as 
the ratio between the concentration of kynurenine and tryptophan, in the control 
medium, CM-hAMTC, CM-MLR or CM-MLR-hAMTC, and in the presence of 0.5 
mM DL-methyl-tryptophan (CM-MLR-hAMTC+MT). (D) Lymphocyte proliferation 
(expressed in cpm), induced by MLR, in the presence of hAMTC cultured with or 
without the addition of DL-methyl-tryptophan. (E) Lymphocyte proliferation 
(expressed in cpm), stimulated with anti-CD3, in presence of 100 µl of control 
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medium or CM derived from untreated (black bar) or 0.5mM DL-methyl-tryptophan-
treated (white bar) hAMTC and hAM cultures. (F-I) Lymphocyte proliferation 
(expressed in cpm) after stimulation with anti-CD3, in presence of 100 µl  of control 
medium or CM derived from untreated (black bar) or indomethacin- (F), ketoprofen- 
(G), niflumic acid- (H) or inhibitors-mix- (I) treated (white bars) hAMTC and hAM 
cultures. Data represent the mean and the SD of at least three independent 
experiments. *=p<0.05, **=p<0.01, ***=p<0.001.
Prostanoids
UltraCulture CM-hMATC CM-hAM
NT NT
Indomethacin 
treated NT
Indomethacin 
treated
Total 
prostanoids <1 542±280 5.8±4 69±6 16±5
PGE2 <1 390±146 <1 24±2 <1
PGD2 <1 67±1 <1 6±1 <1
PGF2α <1 27±13 <1 10±1 <1
Values are expressed in ng/ml
Table 4.3. Prostanoids quantification in UltraCulture medium and CM derived 
from untreated or indomethacin treated hAMTC and hAM. 
In order to determine if PGs are partially or entirely responsible for the 
CMs’ inhibitory effect, we added exogenous PGs to anti-CD3 stimulated T 
cells. While the addition of PGI2 did not inhibit T cell proliferation, the 
addition of  PGF2α, PGD2 and PGE2 had a slight inhibitory effect which 
was detectable when used at concentrations of 10000 ng/ml, 1000 ng/ml 
and 5 ng/ml, respectively. Thus, PGF2α and PGD2 display an inhibitory 
effect when used at a higher concentration than that we observed in CMs 
(Fig. 4.11A and Table 4.3), suggesting the lack of involvement of these in 
CM inhibitory effect. Meanwhile, PGE2 induces a slight reduction of T cell 
proliferation also when used at concentration comparable to that found in 
CM-hAMTC (390±146 ng/ml) and CM-hAM (24±2 ng/ml) (Fig. 4.11A and 
Table 4.3). Interestingly, the addition of  PGE2 induced a consistent and 
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unchanging inhibitory effect on cell proliferation in the range between 1000 
ng/ml and 25 ng/ml (Fig. 4.11A).  
With the aim to mimic the composition of  PGs present in CM-hAMTC or in 
CM-hAM, and to evaluate if  there could be some cooperation between the 
different PGs, we sought out to determine the effects that a mix of  PGs has 
on T cell proliferation. As shown in Figure 4.11B-C the addition of a mix of 
PGs (PGE2 500 ng/ml + PGD2 100 ng/ml + PGF2α 25 ng/ml or PGE2 25 
ng/ml + PGD2 6 ng/ml + PGF2α 10 ng/ml) on stimulated PBMC inhibited 
the cell proliferation, but clearly at lower than that observed with CM-
hAMTC and CM-hAM. 
To further address the role of PGs in the CMs’ inhibitory effect, we also 
added PGs to anti-CD3 stimulated T-cells in the presence of CMs prepared 
following COX inhibition. We observed that the addition of a mix of PGs 
restored the inhibitory effect of the COX-inhibited CMs to approximately the 
level observed with CM from untreated sample (Fig. 4.11B-C). This 
suggests that some other factor(s) present in the CMs could partecipate 
with PGs to the CMs’ inhibitory effects. 
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Figure 4.11. Effect of PGs on the proliferation of stimulated PBMC in 
presence or absence of CMs obtained from hAMTC or hAM treated or not 
with indometahcin. (A) Lymphocyte proliferation, stimulated with anti-CD3, in 
presence of different amount of prostaglandin (PGs): PGD2 (u), PGE2 (☐), 
PGF2α (Δ) or PGI2 (X). (B) Lymphocyte proliferation, stimulated with anti-CD3, in 
presence of 100 µl of control medium (UltraCulture) or CM derived from untreated 
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(CM-hAMTC) or indomethacin treated (CM-hAMTC Indo) hAMTC with (green bars) 
or without (black bars) the addition of a mix of PGs (PGE2 500 ng/ml + PGD2 100 
ng/ml + PGF2α 25 ng/ml). (C) Lymphocyte proliferation, stimulated with anti-CD3, 
in presence of 100 µl  of control  medium (UltraCulture) or CM derived from 
untreated (CM-hAM) or indomethacin treated (CM-hAM Indo) hAM with (white 
bars) or without (black bars) the addition of a mix of PGs (PGE2 25 ng/ml + PGD2 
6 ng/ml + PGF2α 10 ng/ml). *=p<0.05, **=p<0.01, ***=p<0.001.
4.2.2.5 Evaluation of CM-hAMTC and CM-hAM effect on PGs, NO and 
kynurenine production in leukocytes
After having studied which molecules are directly released by hAMTC or 
hAM and associated with inhibitory effect, we questioned whether the CM 
inhibitory effect could be due to the secretion of  these immunomodulatory 
molecules from PBMC. We therefore added CM-hAMTC or CM-hAM on 
PBMC stimulated with anti-CD3 in the presence of the inhibitors 
indomethacin, L-NAME or DL-methyl-tryptophan. The addition of 
indomethacin did not shown any difference in the proliferation level (Fig. 
4.12A), suggesting that PBMC are not induced to produce PGs in presence 
of CMs. Similar results were obtained after the addition of L-NAME and DL-
methyl-tryptophan (Fig. 4.12B-C), suggesting the lack of  involvement of 
IDO and NO in immunomodulation of the CMs.
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Figure 4.12. Inhibition of production of NO, kynurenine, and prostaglandins 
(PGs) in PBMC culture. Lymphocyte proliferation, stimulated with anti-CD3, in 
presence of 100 µl of control medium or CM-hAMTC and CM-hAM with (blue bars) 
or without (black bars) the addition of indomethacin (A), L-NAME (B) or DL-methyl-
tryptophan (C). Data represent the mean and SD of at least three independent 
experiments. *= p<0.05, **= p<0.01, ***= p<0.001 versus PBMC + αCD3.
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5. DISCUSSION
In this study we have demonstrated that soluble factors released in CM 
from the cultures of hAMTC and hAM possess the ability to inhibit T 
lymphocyte proliferation. Importantly, hAMTC and hAM were not stimulated 
prior to CM collection. This is in contrast to MSC derived from BM 
[115,116], which possess an anti-proliferative ability only when cultured in 
the presence of activating stimuli, such as IL-1β, TNF-α or IFN-γ [93]. This 
underlines the functional differences when using MSC from different 
sources, most likely due to the heterogeneity of the MSC populations.
In our study, aimed at defining the inhibitory factor(s) produced by hAMTC, 
we began with the analysis of  IL-6, IL-10, TGF-β and HGF, which are 
already documented to be released by and involved in the 
immunoregulatory activity of MSCs from other sources [94,118-121]. We 
isolated hAMTC from over 80 donors, produced CM from each cell 
population/donor and used them in our analyses. Specific inhibition of 
selected molecules with neutralizing antibodies revealed that HGF and 
TGF-β do not participate in the anti-proliferative effect exerted on T 
lymphocytes by CM-hAMTC and CM-hAM, while neutralization of IL-6 and 
IL-10 showed a slight reversion which did not reach significative difference. 
In order to characterize the nature of  the factor(s) in question, we analyzed 
the thermostability, proteinaceous composition, and the molecular weight of 
molecules contained in the CM-hAMTC. We have demonstrated that the 
inhibitory factor(s) are temperature-stable, possess a small molecular 
weight (<3 kDa) and are most likely of  a non-proteinaceous nature. We 
favour the non-proteinaceous nature of  some of these compounds because 
CM treatment with protease which induced 90% protein degradation still did 
not result in a significant reduction in the capability of  the CM to decrease 
T-cell proliferation. These observations brought us to focus on the potential 
involvement of  small molecules. Some authors have reported that NO and 
IDO play critical roles in the suppression of T-cell proliferation when using 
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BM-MSC [122,123]. Our results clearly demonstrate that these factors are 
not involved, neither directly nor as mediators in the production of other 
inhibitory factors, as proven by blocking their synthesis pathways using 
selective inhibitors for IDO and NO synthase (e.g. methyl-tryptophan and L-
NAME, respectively). No effects were seen either when the inhibitors were 
used on hAMTC during CM production, or during the incubation of  CM-
hAMTC with CD3-stimulated PBMC, thus implying that PBMC do not 
produce NO or IDO in reaction to (after coming in contact with) stimuli 
found in the CM of hAMTC. 
Interestingly, we have shown that hAMTC and hAM release PGs in culture 
and that these are responsible for a significant part of  the inhibitory effect. 
Moreover, the chemical-physical nature of PGs is in agreement with the 
high stability and low  molecular weight of  the factors we characterized in 
CM-hAMTC. Nevertheless, treatment with COX inhibitors was unable to 
completely abolish the inhibitory effect of CM-hAMTC and CM-hAM, 
suggesting the involvement of other factors. Consistent with this hypothesis 
is the fact that the addition of a mix of PGs (that mimics those present in 
CM) on stimulated PBMC induces an inhibition of  proliferation but at a 
lower level than that observed with CM-hAMTC and CM-hAM. Furthermore, 
we have shown that the addition of a mix of PGs to anti-CD3 stimulated T 
cells in the presence of CM prepared following COX inhibition rescues the 
inhibitory effect to the level observed with CM from untreated hAMTC. 
Taken together, these results indicate that PGs are just one of the key 
effector molecules involved in the immunomodulatory activity of the 
amniotic membrane. The influence of other factors is also suggested by our 
investigations on the molecular weight of  soluble factors in CM-hAMTC. 
Indeed, taken individually, the only fraction able to significantly decrease 
lymphocyte T cell proliferation was the one < 3 kDa, even though not to the 
extent of the unfractionated CM-hAMTC, thus suggesting that other 
components are also responsible for the inhibitory effect. The inhibitory 
effect obtained with unfractionated or the pool of fractions was also 
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observed by mixing the two fractions < 3 kDa and >100 kDa, suggesting 
the contribution of molecules within these molecular weight ranges to the 
immunomodulatory effect of the CM from the amniotic-derived cells.
Some reports suggest that factors such as NO, PGs, and IDO activity are 
usually active in a multi-cellular environment, which includes not only MSC 
but also PBMC or other cell types [124,125]. In order to distinguish which 
cells could produce PGs (MSC or PBMC), we used COX inhibitors both 
during the generation of CM from hAMTC and from hAM, and also during 
the culture of the generated CM (CM-hAMTC and CM-hAM) with stimulated 
PBMC. We observed that PGs are produced and detected in CM-hAMTC 
and CM-hAM, while it is not produced by PBMC stimulated by the CM. 
It is noteworthy that at present we have performed our analyses only with 
CM derived from unstimulated cells. This is because our first aim was to 
understand which inhibitory factor(s) are produced by hAMTC in the 
absence of particular stimuli or particular culture conditions. Eventually, in 
follow-up studies we aimed to determine for the conditions that can change/
enhance the spectrum of  factors released by these cells. Actually, it has 
been reported that the exposure of human amniotic mesenchymal cells to 
inflammatory stimuli (such as to the action of  IFN-γ or IL-1β), induces 
changes in the expression of some cellular surface markers [126,127] and 
the upregulation of secretion of  factors involved in inflammation (such as 
TGF-β [128], IDO [127,128], IL-8 [126], IL-6 [126], serpin E1 [126], IP10 
[126], sCD54 [126], MCP-1 [126] and PGs [128,129]). Moreover, this 
exposure also increases the anti-proliferative ability of human amniotic 
mesenchymal cells when co-cultured in contact with PBMC [126,127]. 
These fragmented results suggest that the state of activation of amnion-
derived mesenchymal cells may also affect their capability to modulate cell 
proliferation. Likewise, we have previously demonstrated that hAMTC 
inhibit the proliferation of T lymphocytes [4] and also of  cancer cell lines 
from hematopoietic and non-hematopoietic origin [106], in both cell-cell 
contact and transwell co-cultures, and with a higher level of inhibition in a 
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cell-cell contact settings. It could be possible that the contact between cells 
leads to the release of some other factors involved in the inhibition of the 
lymphocytes proliferation. Therefore, it remains to be elucidated if there is 
any qualitative and/or quantitative difference in the pattern of components 
of the supernatants, including PGs, when obtained from stimulated cells 
and from cells that are cultured in cell-cell manner.
This study did not reveal any appreciable differences concerning the 
inhibition of  lymphocyte proliferation between the CM derived from the 
whole amniotic membrane and the CM derived from cells isolated from the 
membrane. This suggests that the amniotic membrane could be an 
interesting source of  soluble factors, without referring to extensive cell 
preparation. Even though the presence of  the cells derived from both the 
mesenchymal and the epithelium layers of amniotic membrane might 
contribute to produce a supernatant with different composition.
In conclusion, in this study we have shown for the first time that the anti-
proliferative effect of hAMTC is not related to the presence of  external 
stimuli. hAMTC and hAM are indeed able to release soluble factors with 
inhibitory effects when cultured in non-stimulated conditions, proving that 
the effect is an intrinsic characteristic. Moreover, we have also provided 
evidence that this effect seems to be mediated by low  molecular weight, 
non-protein, thermostable compound(s) present in CM-hAMTC and CM-
hAM. Finally we provide evidence that prostaglandins are one of  the key 
effector molecules in the immunomodulatory activity of  the human amniotic 
membrane, while this activity minimally involves IL-6 and IL-10, but not 
IDO, NO, TGF-β or HGF instead proposed to be involved in anti-
proliferative action of MSC of other sources.
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6. FUTURE PROSPECTS AND BIOMEDICAL APPLICATIONS
Further studies are clearly necessary for complete characterization of  the 
soluble factors released by mesenchymal cells derived from the amniotic 
membrane. Indeed, full identification of the factors involved in the 
antiproliferative effects of hAMTC will undoubtedly be essential for a 
complete understanding of the mechanisms responsible for this 
phenomenon. 
Characterization of  these mechanisms will be of particular importance for 
the development of  future clinical approaches using soluble factors derived 
from mesenchymal cells of the amniotic membrane, in particular for the 
treatment of diseases characterized by an altered inflammatory response.
Moreover, of particular significance is the possibility that a cell-free 
treatment based on the use of CM-hAMTC could potentially replace cell 
transplantation, particularly when tissue repair via paracrine bioactive 
molecules is required. This strategy also offers a series of added 
advantages: 
• CM-hAMTC can be produced easily and in large quantities;
• it can be stored efficiently and easily; 
• as a cell-free treatment, it can drastically reduce the risk of  adverse 
immunological reactions, infectious risks and other potential long-term 
negative effects associated with the presence of exogenous cells; 
• CM-hAMTC could be administered easily via intravenous injection, 
avoiding clot formation and capillary entrapment.
In this context, further study of  the CM-hAM as a tool for regenerative 
medicine is also warranted due to its low  production cost and minimal 
requirement for manipulation in order to obtain soluble factors.
In addition, the study of how  different stimulatory environments may 
modulate the production of immunomodulatory factors by amnion-derived 
cells also represents another avenue of interest, as it is conceivable that 
the anti-proliferative efficacy of  supernatants could be optimized through 
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manipulation of  hAMTC culture conditions (eg. concentration, days of 
culture, cytokine stimulation, etc.).
Finally, studies both in vitro and in selected animal models will no doubt 
provide valuable information regarding the immunomodulatory effects of the 
CM-hAMTC and CM-hAM compared to those observed when using cells 
isolated from the amniotic membrane.
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